Physio-Control's Lifepak 12 Stimulates Wall Street - Stock Up 31% In April
This article was originally published in The Gray Sheet
Physio-Control's release of higher than anticipated first-quarter results April 20, driven by strong initial demand for the firm's recently introduced Lifepak 12 external defibrillator/monitor, translated into a stock price increase of 31.4% for the month. The issue closed April at 23 after gaining 5-1/2 points.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.